LVS DEC. 21 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Las Vegas Sands Corp. – LVS

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Las Vegas Sands Corp. (NYSE: LVS) between February 27, 2016 and September 15, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=las-vegas-sands-corp&id=2452 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=las-vegas-sands-corp&id=2452

If you wish to serve as lead plaintiff, you must move the Court before the December 21, 2020 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:   Marina Bay Sands, a Las Vegas Sands resort in Singapore, casino control measures pertaining to fund transfers had weaknesses; the Marina Bay Sands’ casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company’s anti-money laundering procedures; the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; Las Vegas Sands had inadequate disclosure controls and procedures; consequently, all the foregoing issues were untimely disclosed; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756



DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action  – IPHA

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=innate-pharma-s-a&id=2443 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=innate-pharma-s-a&id=2443

If you wish to serve as lead plaintiff, you must move the Court before the December 22, 2020 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Innate touted the results of their various Phase 2 trials as being within expectations; Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756



VA New Orleans Receives Spinal Cord Rehabilitation Exoskeleton From National Nonprofit SoldierStrong

NEW ORLEANS, Dec. 18, 2020 (GLOBE NEWSWIRE) — SoldierStrong, a national nonprofit organization dedicated to improving the lives of Veterans through the donation of revolutionary medical technologies to Veterans Affairs and other medical centers across the country, donated an exoskeleton to the New Orleans Veterans Medical Center today.

Since SoldierStrong’s inception following the tragic events of 9/11, the Stamford, Conn.-based group has donated more than $3 million of medical devices to help injured Veterans. Today’s donation is the organization’s 24th exoskeleton donation, including the 20th one to the VA system. Currently, 35,000 Veterans have access to exoskeleton rehabilitation devices. 

“VA has an established tradition of using the most advanced technologies to provide cutting-edge rehabilitation care to Veterans,” said Medical Center Director Fernando Rivera. “SoldierStrong’s donation of this cutting-edge device will help us continue to maximize the independence and improve the quality of life of the Veterans that we treat.”

SoldierStrong co-founder and chairman Chris Meek said the organization’s goal to make exoskeleton suits available to every Veteran in need throughout as many states as possible was a significant factor in the local donation. This is the second exoskeleton donated by SoldierStrong in the state, allowing for use of the device to become more accessible for a wider array of Louisiana’s Veterans. 

“Many Veterans who sustain spinal injuries are young men and women, which means individuals often must navigate through decades of health-related challenges when these devastating injuries occur,” Meek said. “Early rehabilitation therapy with an exoskeleton has shown to have lasting positive effects on both the physical and often overlooked mental health recovery for patients who use them. That is why we feel it is so important that exoskeleton devices are made accessible to as many Veterans as possible — young and older — at the onset of their journey of recovery, in order to positively shape and impact mobility in the decades ahead. We are honored to work with the New Orleans VA Medical Center in making our goal a reality.” 


About SoldierStrong


SoldierStrong, previously known as SoldierSocks, helps American patriots literally take their next steps forward. Through educational scholarships and by harnessing the most innovative technology in advanced rehabilitation, we help our returning service men and women to continue moving in the only direction they should know – forward. Nearly every dollar SoldierStrong receives goes towards direct support of American patriots so that they can re-acclimate to civilian life. Our organization works to remind those men and women who sacrificed so much that we are forever thankful. For more information, visit: https://www.soldierstrong.org/

CONTACT: ERIC WOOLSON
(515) 681-3967



GOLFTEC Vice President of Instruction & CEO Take Top Honors In Colorado PGA Awards

Englewood, CO, Dec. 18, 2020 (GLOBE NEWSWIRE) — (Denver, CO) GOLFTEC, the world leader in golf improvement and club fitting, announced a pair of high honors from the Colorado PGA Section; Vice President of Instruction, Nick Clearwater, named the 2020 Colorado PGA Teacher of the Year and CEO Joe Assell was awarded the prestigious Warren Smith Award.

The Colorado PGA Special Awards are presented each spring by a special committee including two or more Board of Directors. For 2020, this included Special Awards Committee Chair, Keith Stilwell, PGA, Co-Chairs, Andy Benson, PGA, and Bobby Quarantino, PGA, along with the 2019 Special Award Winners, all of whom were tasked with identifying the best of the best in Colorado for 2020.

Nick Clearwater, Vice President of Instruction for GOLFTEC, received the 2020 Colorado PGA Teacher of the Year award. Clearwater has been a speaker, presenter and instructor all over the world and has been awarded every honor offered to teachers by Golf Digest. The Golf Channel has shown over 300 videos he has scripted, been featured in and produced as well as another 300 he produced for other coaches. Clearwater also spearheads GOLFTEC’s free lesson program for aspiring PGA Professionals to help them pass their PAT with any of their 400 corporate coaches, his team or himself.

“To be named Teacher of the Year for Colorado is a huge honor,” said Clearwater. “Living in Colorado, working and teaching here, it means a lot to me to have the local Section recognize those efforts with this prestigious award. Helping people play better golf is at the heart of everything we do at GOLTEC, and drives not only myself, but all of our 700+ Coaches each and every day. I’m very grateful to be able to do what I do every day, and this just reinforces I am on the right path.”

Joe Assell, GOLFTEC CEO and Co-Founder, received the Warren Smith Award – the Colorado Section’s lifetime achievement award. The Warren Smith Award is given to a PGA Professional for his/her outstanding contributions to the game and to the Section. Assell has served two, three-year terms on the Colorado PGA Board of Directors and has been on the Colorado PGA Finance Committee for over 15 years, giving back to the Section and the organization as a whole that means so much to him.

“I am humbled and honored to receive the Warren Smith Award for 2020,” said Assell. “As a PGA Member, I get up every day and run a company providing great life and career opportunities for hundreds of other PGA Professionals. Warren Smith mentored so many at Cherry Hills, the same club where I started, and where the idea for GOLFTEC was born. To be able to follow in his footsteps, in my own way, and help the next generation of PGA Professionals and be recognized with an award bearing his name? That means everything to me.”

GOLFTEC is a leading employer of PGA Professionals in the world and offers Free Lessons for aspiring PGA Professionals to help them pass their PAT test. For more information, please visit golftec.com/pat

(About GOLFTEC)

Since 1995, GOLFTEC has become the world’s largest provider of golf lessons and premium club fittings, operating more than 200 corporately-owned and franchised Training Centers in all major U.S. cities, Canada, China, Japan, Hong Kong and Singapore. Its highly-trained coaches leverage leading-edge technology for a completely fact-based approach to instruction, practice and club fitting. GOLFTEC’s leadership position in golf improvement is augmented by its SwingTRU Motion Study – the largest ever conducted on golf swing mechanics.

Attachments



CJ Perry, PGA
GOLFTEC
303.374.4039
[email protected]

Capgemini Recognized as a Top Company for Executive Women

 Capgemini Recognized as a Top Company for Executive Women

NEW YORK–(BUSINESS WIRE)–Capgemini has been named one of the 2020+ Top Companies for Executive Women by Working Mother Media (WMM). This list is the most definitive list of top workplaces for women who want to advance through the corporate ranks, and celebrates companies that champion women’s advancement, with a focus on succession planning, profit-and-loss roles, gender pay parity, support programs and work-life balance programs.

“It’s more important than ever to have a culture and talent strategy that enables human potential that not only matches the rich make up of society, but supports the ambitions of positive change and progress for our communities,” says John Mullen, President of Capgemini’s North America Business Unit and Group Executive Committee Member. “We are proud of this recognition and will continue to do our part to create a diverse team that promotes and nurtures successful women.”

“Because what gets measured gets done, our Top Companies list stresses the number of women in senior positions,” says Betty Spence, President of the National Association for Female Executives. “Most important, we are the only organization that counts women holding revenue-generating operations positions with profit-and-loss responsibility, as those are the jobs that are the path to the top. Companies need to pay attention because that number dropped in the past year, even pre-COVID-19.”

Capgemini continues to be recognized as a responsible and inclusive employer and is committed to empowering and growing the number of women in leadership. Capgemini’s own Women’s Leadership Development Program, a structured, ongoing leadership development program, provides training, mentoring, career objective-setting and outside coaching to women. Capgemini also promotes diversity and inclusion through the endorsement of 11 Employee Resource Groups in North America, and its Inclusion Leadership Advisory Council (ILAC) which focuses on diverse recruitment, employee development and retention initiatives for under-represented communities. Currently, there are more than 3000 North American employees participating across these groups.

In addition to this distinction from WMM, Capgemini was also nationally recognized by WMM in the Diversity Best Practices Inclusion Index earlier this year and the Human Rights Campaign Foundation as a Best Place to work for LGBTQ Equality.

Methodology

The 2020+ Top 75 Companies application includes more than 200 questions on topics including female representation at all levels, but especially the corporate officer and profit-and-loss leadership ranks. The application, based on 2019 data, tracks and examines how many employees have access to programs and policies that promote advancement of women and how many employees take advantage of them, plus how companies train managers to help women advance. To be considered, companies must have a minimum of two women on their boards of directors, a US-based CEO and at least 1,000 US employees.

About Capgemini

Capgemini is a global leader in consulting, digital transformation, technology, and engineering services. The Group is at the forefront of innovation to address the entire breadth of clients’ opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. A responsible and multicultural company of 265,000 people in nearly 50 countries, Capgemini’s purpose is to unleash human energy through technology for an inclusive and sustainable future. With Altran, the Group reported 2019 combined global revenues of €17 billion.

Visit us at www.capgemini.com.

About WMM

Working Mother Media (WMM) is a strategic professional services firm that partners with leading companies to build inclusive talent strategies by providing the tools needed to maximize the business benefits of DE&I. With four decades of expertise in what drives cultures of equity and belonging, powered by a research-based, data-driven understanding of the employee experience, WMM continues to champion a more equitable future. To learn more, visit workingmother.com.

Abby Evans

Tel.: 775-560-7175

E-mail: [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Consumer Technology Women Other Technology Software Consulting

MEDIA:

Logo
Logo

GOLFTEC Coach Accomplishments: Doug Strawbridge & Carlos Sainz Jr.

Englewood, CO, Dec. 18, 2020 (GLOBE NEWSWIRE) — (Denver, COGOLFTEC, the world leader in golf improvement and club fitting, announced a high honor from the South Texas PGA Section; GOLFTEC Houston Regional Manager, Doug Strawbridge and GOLFTEC Upper Kirby Certified Personal Coach, Carlos Sainz Jr. Doug Strawbridge won the 2020 South Texas PGA Section-Eastern Chapter Harvey Penick Teacher of the Year award and Carlos Sainz Jr. won the 2020 South Texas PGA Section Omega Player of the Year award.

Doug Strawbridge, the Houston Regional Manager and Director of Instruction for GOLFTEC Upper Kirby in Houston, TX has been honored by the South Texas PGA Section-Eastern Chapter with the Harvey Penick Teacher of the Year award for 2020. Strawbridge has been teaching for 18 years and has taught over 30,000 lessons, and was also named to the Golf Digest’s Best in State List for top instructors in Texas.

Carlos Sainz Jr., a Certified Personal Coach with GOLFTEC Upper Kirby in Houston, TX has been honored by the South Texas PGA Section with the Omega Player of the Year award for 2020. Sainz has been with GOLFTEC since 2019 and prior to joining GOLFTEC, he has played professional golf on various tours including the PGA Tour. “We are very proud of Carlos,” said Doug Strawbridge. “He is a dedicated and passionate professional focused on helping people play better golf. This award recognizes that passion and is well deserved.” In 2020 Carlos won five South Texas PGA tournaments:

  • TPX Communications Championship
  • National Car Rental Assistant Championship
  • Spring Classic
  • Tradition Championship
  • Memorial Championship

Doug and Carlos both teach lessons at GOLFTEC Upper Kirby in Houston, TX, a 2,800 square feet Training Center with five teaching / practice bays along with a putting green, and the company’s enhanced custom club fitting program. The TOUR-like fitting experience combines swing characteristics with ball flight data to help identify optimal golf equipment for each student. An array of clubhead/shaft options are available to perfectly match players of any skill level with the clubs that best meet their needs. Nearly 75% of all golfers who went through a club fitting in 2020 gained an average of 25 yards over their previous equipment.

About GOLFTEC

GOLFTEC is the world leader in instruction with over 200 locations worldwide. As a company, GOLFTEC is closing in on 10 million lessons taught over 25 years. GOLFTEC’s world-renowned teaching technology includes advanced motion measurement, video analysis, premium launch monitors and putting lessons powered by TECPUTT. The company’s enhanced custom club fitting program combines swing characteristics with ball flight data to help identify optimal equipment for each student. In 2019, GOLFTEC gave over 34,000 club fittings. The majority of GOLFTEC Certified Personal Coaches are PGA Professionals who have each taught thousands of lessons.

Attachments



CJ Perry, PGA
GOLFTEC
303.374.4039
[email protected]

C STOCK DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Citigroup Inc. – C

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Citigroup Inc. (NYSE: C) between January 15, 2016 and October 12, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=citigroup-inc&id=2503 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=citigroup-inc&id=2503

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (a) Citigroup’s failure to implement and maintain an enterprise-wide risk management and compliance risk management program, internal controls, or a data governance program commensurate with the Company’s size, complexity, and risk profile; (b) Citigroup’s failure to establish an effective risk governance framework; (c) Citigroup’s failure to establish enterprise-wide risk management policies, standards, and frameworks necessary to adequately identify, measure, monitor, and control risks ; (d) Citigroup’s failure to establish effective front-line units, independent risk management, internal audit, and control functions; (e) Citigroup’s failure to develop and execute on a comprehensive plan to address data governance deficiencies, including data quality errors and failure to produce timely and accurate management and regulatory reporting; (f) that Citigroup had failed to make the investments required to address its regulatory shortcomings; (g) that the Company had failed to implement and establish the requisite internal controls, risk management and data governance processes to comply with regulatory requirements, existing consent orders, and applicable laws and regulations; (h) that the Company was currently exposed to significant financial and operational risk, including risk from outdated and manual processes that left the Company susceptible to material accounting errors; (i) that the Company was currently suffering from material deficiencies in its policies, procedures and practices applicable to data integrity and data governance and had failed to develop and execute on a plan to address these deficiencies as required by regulators; (j) that the Company lacked the required personnel with appropriate training, experience and authority to implement the required risk management and internal controls; and (k) that as a result of the foregoing, the Company had engaged in unsafe and unsound business practices that exposed it to heightened regulatory, legal, business and reputational risks. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected] 
tel: (800) 991-3756



Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

— Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addressable Patient Population —

— Oral XPOVIO is Now the Only Multiple Myeloma Drug Indicated as Part of an Approved, Once-Weekly Velcade® (bortezomib) Combination Regimen —

— First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 –

— FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date —

— Karyopharm to Hold an Investor Conference Call and Webcast Today at 1:00 p.m. ET —

PR Newswire

NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO was previously approved under the FDA’s Accelerated Approval Program for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

“Today’s U.S. approval broadens the existing label for XPOVIO and allows Karyopharm to offer a new, highly active, treatment option to a significantly expanded patient population,” said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. “We believe the expanded reach of XPOVIO will address a critical need for patients with multiple myeloma given its novel mechanism of action, convenient oral administration and established rapid and sustained efficacy profile. The XPOVIO label expansion approval was supported by the pivotal Phase 3 BOSTON study, which was recently published in The Lancet. This approval was made possible by the patients, caregivers and physicians who participated in the clinical development of XPOVIO, as well as our global, dedicated Karyopharm team that has worked tirelessly to advance this innovative therapy to the greater multiple myeloma community.”

“New treatments for multiple myeloma remain a critical need for both patients and their treating physicians,” said Paul Richardson, MD, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and co-senior author of the BOSTON study publication. “Selinexor with once weekly bortezomib-dexamethasone (SVd) demonstrated encouraging and highly significant results in the Phase 3 BOSTON study, including a 47% improvement in progression-free survival versus standard twice weekly bortezomib-dexamethasone (Vd). Patients receiving SVd had approximately 35% fewer clinic visits compared to those receiving the standard, twice-weekly Vd regimen, thus receiving 40% less bortezomib and 25% less dexamethasone as compared with the control arm in the first 24 weeks of therapy. This once-weekly dosing feature helps makes the SVd regimen attractively simple. Importantly, patients achieved a significantly higher overall response of 76% with once-weekly SVd compared with the standard control arm therapy, and higher response rates were observed regardless of prior therapies received, the presence of high-risk cytogenetics, renal impairment or advanced age. Finally, adverse events with SVd were important but generally self-limiting, reversible, and proved manageable with dose modifications and aggressive supportive care, as well as generating significantly lower rates of peripheral neuropathy compared to the control group. As the only approved nuclear export inhibitor that has demonstrated a strong synergistic effect with a proteasome inhibitor such as bortezomib, selinexor has, in my opinion, the potential to meet a current treatment gap for our multiple myeloma patients in need of new therapeutic options.”

“We plan to immediately launch XPOVIO in this earlier-line indication by leveraging our established commercial infrastructure and growing account base of academic institutions and community-based oncology practices,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “In parallel to our commercial initiatives in the U.S., we continue to collaborate with the European Medicines Agency (EMA) on the Marketing Authorization Application (MAA) of XPOVIO with the goal of further growing the global reach of XPOVIO to more patients in need.”

In addition to multiple myeloma, XPOVIO is also approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

About the Phase 3 BOSTON Study

The FDA approval of XPOVIO’s expanded indication is supported by the results of the BOSTON study, a multi-center, Phase 3, randomized study (NCT03110562), which evaluated 402 adult patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly XPOVIO (selinexor) in combination with once-weekly Velcade® (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade® plus dexamethasone (Vd). The primary endpoint of the study was progression-free survival (PFS) and key secondary endpoints included overall response rate (ORR), rate of peripheral neuropathy, and others. Additionally, the BOSTON study allowed for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease verified by an Independent Review Committee (IRC). The BOSTON study was conducted at over 150 clinical sites internationally.

Although the study had one of the highest proportions of patients with high-risk cytogenetics (~50%) as compared with other Velcade-based studies in previously treated multiple myeloma, the median PFS in the SVd arm was 13.9 months compared to 9.5 months in the Vd arm, representing a 4.4 month (47%) increase in median PFS (hazard ratio of 0.70; p=0.0075). The SVd arm also demonstrated a significantly greater ORR compared to the Vd arm (76.4% vs. 62.3%, p=0.0012). Importantly, SVd therapy compared to Vd therapy showed consistent PFS benefit and higher ORR across several important subgroups.

In addition, the following results favored SVd therapy as compared to Vd therapy:

  • SVd therapy demonstrated a significantly higher rate of deep responses, defined as ≥ Very Good Partial Response compared to Vd therapy (44.6% vs. 32.4%) as well as a longer median duration of response (20.3 months vs. 12.9 months). Additionally, 17% of patients on the SVd arm achieved a Complete Response or a Stringent Complete Response as compared to 10% of patients receiving Vd therapy. All responses were confirmed by an IRC.
  • Peripheral neuropathy (PN) rates were significantly lower on SVd compared to Vd (32% vs. 47%). In addition, PN rates ≥ Grade 2 were also significantly lower in the SVd arm compared to the Vd arm (21% vs. 34%).

The most common adverse reactions were cytopenias, along with gastrointestinal and constitutional symptoms and were consistent with those previously reported from other selinexor studies. Most adverse reactions were manageable with dose modifications and/or standard supportive care. The most common non-hematologic adverse reactions were fatigue (59%),nausea (50%), decreased appetite (35%), and diarrhea (32%) and were mostly Grade 1 and 2 events. The most common Grade 3 and 4 adverse reactions were thrombocytopenia (43%), lymphopenia (38%), fatigue (28%) and anemia (17%).

The full results from the BOSTON study were recently published in The Lancet and can be found here.

Conference Call Information

Karyopharm will host a conference call today, Friday, December 18, 2020, at 1:00 p.m. Eastern Time, to discuss the FDA’s approval of the expanded XPOVIO label. To access the conference call, please dial (877) 870-4263 (local) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call will be available under “Events & Presentations” in the Investor section of the Company’s website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company’s website approximately two hours after the event.

About Multiple Myeloma

According to the National Cancer Institute (NCI), multiple myeloma is one of the most common types of blood cancer in the U.S. with more than 32,000 new cases each year and over 140,000 patients living with the disease. It is most frequently diagnosed among people aged 65-74 years old. Despite recent therapeutic advances, there is currently no cure and most patients’ disease will typically progress following treatment with currently available therapies. According to the NCI, nearly 13,000 deaths due to multiple myeloma are expected in the U.S. in 2020.

About XPOVIO® (selinexor)

XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. Karyopharm received accelerated U.S. Food and Drug Administration (FDA) approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor in this same RRMM indication. Karyopharm’s supplemental New Drug Application (sNDA) requesting an expansion of its indication to include the treatment for patients with multiple myeloma after at least one prior therapy was approved by the FDA on December 18, 2020. In June 2020, Karyopharm received accelerated FDA approval of XPOVIO for its second indication in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including as a potential backbone therapy in combination with approved myeloma therapies (STOMP), in liposarcoma (SEAL) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharm’s clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov.

For more information about Karyopharm’s products or clinical trials, please contact the Medical Information department at:

Tel: +1 (888) 209-9326
Email: [email protected]

IMPORTANT SAFETY INFORMATION

Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection.

Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients.

Nausea/Vomiting/
Diarrhea
: Provide prophylactic antiemetics or treatment as needed.

Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment and provide nutritional support, fluids, and electrolyte repletion as clinically indicated.

Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia. 

Monitor sodium level at baseline and throughout treatment.

Serious Infection: XPOVIO can cause serious and fatal infections. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.

Neurological Toxicity
: XPOVIO can cause life-threatening neurological toxicities.

Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.

Advise patients to refrain from driving and engaging in hazardous occupations or activities until the neurological toxicity fully resolves. Institute fall precautions as appropriate.

Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

Cataracts: New onset or exacerbation of cataract has occurred during treatment with XPOVIO. The incidence of new onset or worsening cataract requiring clinical intervention was reported.

ADVERSE REACTIONS

The most common adverse reactions (ARs) (≥20%) in patients with multiple myeloma who received SVd were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.

Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

Fatal ARs occurred in 6% of patients within 30 days of last treatment. Serious ARs occurred in 52% of patients. Treatment discontinuation rate due to ARs was 19%. The most frequent ARs requiring permanent discontinuation in >2% of patients included fatigue, nausea, thrombocytopenia, decreased appetite, peripheral neuropathy and vomiting. Adverse reactions led to XPOVIO dose interruption in 83% of patients and dose reduction in 64% of patients.

USE IN SPECIFIC POPULATIONS

No overall difference in effectiveness of XPOVIO was observed in patients >65 years old when compared with younger patients. Patients ≥65 years old had a higher incidence of discontinuation due to an adverse reaction (AR) and a higher incidence of serious ARs than younger patients.

The effect of end-stage renal disease (CLCR <15 mL/min) or hemodialysis on XPOVIO pharmacokinetics is unknown.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch
.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma and in December 2020 in combination with Velcade® (bortezomib) and dexamethasone as a treatment for patients with multiple myeloma after at least one prior therapy. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s expectations and plans relating to XPOVIO for the treatment of patients with relapsed or refractory multiple myeloma or relapsed or refractory diffuse large B-cell lymphoma; commercialization of XPOVIO or any of its drug candidates and the commercial performance of XPOVIO; submissions to, and the review and potential approval of selinexor by, regulatory authorities, including the Company’s regulatory strategy, the anticipated availability of data to support such submissions, timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways; the expected design of the Company’s clinical trials; and the therapeutic potential of and potential clinical development plans for Karyopharm’s drug candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO; that regulators will agree that selinexor qualifies for conditional approval in the European Union as a result of data from the STORM study or confirmatory approval in the European Union based on the BOSTON study in patients with multiple myeloma; or that any of Karyopharm’s drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm’s drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm’s drug candidate portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic could disrupt Karyopharm’s business more severely than it currently anticipates, including by negatively impacting sales of XPOVIO, interrupting or delaying research and development efforts, impacting the ability to procure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, planned regulatory milestones and timelines, or inconveniencing patients; the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; the ability to retain regulatory approval of XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; Karyopharm’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development or regulatory approval of drug candidates by Karyopharm’s competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protection for any product or product candidate. These and other risks are described under the caption “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which was filed with the Securities and Exchange Commission (SEC) on November 2, 2020, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

XPOVIO®(selinexor) is a registered trademark of Karyopharm Therapeutics Inc. Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited.

Cision View original content:http://www.prnewswire.com/news-releases/karyopharm-announces-fda-approval-of-xpovio-selinexor-as-a-treatment-for-patients-with-multiple-myeloma-after-at-least-one-prior-therapy-301196120.html

SOURCE Karyopharm Therapeutics Inc.

Deerfield Healthcare Technology Acquisitions Corp. Announces Proposed Business Combination to Form CareMax

Deerfield Healthcare Technology Acquisitions Corp. Announces Proposed Business Combination to Form CareMax

CareMax is a Technology-Enabled Provider of Value Based Primary Healthcare to Seniors

NEW YORK & MIAMI–(BUSINESS WIRE)–Deerfield Healthcare Technology Acquisitions Corp. (“DFHT”) (NASDAQ: DFHT, DFHTW, DFHTU), a special purpose acquisition company sponsored by an affiliate of Deerfield Management Company, L.P. (“Deerfield”) and Richard Barasch, a veteran healthcare public company executive and investor, announced today that it has entered into a definitive agreement for a business combination with CareMax Medical Group, LLC (“CareMax Medical Centers”) and IMC Medical Group Holdings, LLC (“IMC Health”), technology-enabled providers of value-based care to seniors. Following the business combination, DFHT expects to be renamed CareMax, Inc. (“CareMax” or “the Company”) and will remain listed on the NASDAQ stock market under a new ticker symbol.

Upon closing, CareMax will operate 26 wholly owned medical centers in South and Central Florida, servicing approximately 16,000 Medicare Advantage members under value-based contracts, as well as 36,000 Managed Medicaid and Affordable Care Act patients. The Company expects to have partnerships with nineteen payors, including affiliates of Anthem, Humana, Florida Blue, United Healthcare, and Centene.

In addition, the Company will own the CareOptimize LLC (“CareOptimize”) technology platform employed by all of its owned centers as well as third party clients across the country. CareOptimize features proprietary point of care software that supports physicians with efficient medical utilization, enhanced risk management, pharmacy management, and specialist network development.

Seasoned Management Team

CareMax’s management team will be comprised of seasoned industry professionals, led by Chief Executive Officer Carlos de Solo. Bill Lamoreaux, currently CEO of IMC Health, will become Executive Vice President of CareMax.

Mr. de Solo founded CareMax Medical Centers in 2011 and has nurtured its growth to become an end to end senior care delivery system. Prior to joining IMC Health, Mr. Lamoreaux has held executive management positions at several national and regional health insurers.

Richard Barasch will remain Executive Chairman of the Company upon closing of the business combination. He was formerly Chairman and CEO of Universal American Corp., which was a pioneer in bringing value-based care and physician partnerships to Medicare Advantage beneficiaries. Mr. Barasch also serves as Chairman of AdaptHealth Corp. (Nasdaq: AHCO), which came public in 2019 via a business combination with DFB Healthcare Acquisitions Corp.

Consideration

The total consideration for CareMax Medical Center’s business, including Care Optimize, will be approximately $364 million and, net of debt, the current equity holders will receive 68% in cash and 32% in shares of common stock. The equity holders of CareMax Medical Centers are primarily the founders and executives of the company.

The total consideration to IMC Health equity holders will be $250 million and, net of debt, the current IMC Health equity holders will receive 45% in cash and 55% in shares of common stock. The equity holders of IMC Health include Comvest Partners, a private equity firm located in West Palm Beach, Florida, and Athyrium Capital Management, a private equity firm located in New York, NY.

In addition, current equity holders of CareMax Medical Centers and IMC Health will be entitled to receive an additional earn out payment of up to 6.4 million shares of CareMax common stock, with 50% of those shares vesting if the stock of the Company trades at or above $12.50 during in first 12 months after closing and the balance of the unvested shares vesting if the stock of the Company trades at or above $15.00 during the first 24 months after closing on a volume weighted average price basis for any 20 of 30 trading days for both periods.

Financing

In addition to the approximately $144 million held in the DFHT Trust Account, premier healthcare investors, including Deerfield, Fidelity Management & Research, LLC, Eminence Capital, LP, funds and accounts managed by BlackRock, and Maverick, have committed to purchase over $400 million of shares of common stock of the Company at $10.00 per share through a private placement in public entity (a “PIPE”). In addition, RBC Capital Markets, LLC has provided committed debt financing in connection with the business combination.

Assuming no redemptions of DFHT public shares, the current owners of CareMax Medical Centers and IMC Health will collectively own 27%, Deerfield will own approximately 18%, other DFHT stockholders (including other PIPE investors) will own 51%, DFHT’s sponsor will own 4% respectively of the issued and outstanding shares of common stock of CareMax immediately following the closing.

DFHT estimates that, assuming no redemptions of DFHT shares, the Company will have an initial market capitalization of approximately $800 million, with approximately $233 million of cash on the balance sheet. The Company expects to use this capital to accelerate its acquisition program and invest in de novo centers.

The combined Company’s total Pro Forma enterprise value of approximately $692 million at closing represents: i) 1.7x FY21(E) revenue and 13.2x FY21(E) Pro Forma Adjusted EBITDA (including synergies and excluding acquisitions); ii) 1.3x FY21(E) revenue and 10.4x FY21(E) Pro Forma Adjusted EBITDA (including the full year effect of acquisitions).

Please refer to the investor presentation furnished with DFHT’s Current Report on Form 8-K for details on the pro-forma financials of the Company and its Non-GAAP Financial Measures.

Delivering “Whole Person” Health Care

CareMax’s 26 medical centers offer 24/7 access to care and provide a comprehensive suite of high-touch health care and social services to its patients, including primary care, specialty care, telemedicine, health & wellness, optometry, dental, and transportation. CareMax’s differentiated healthcare delivery model, focused on care coordination with vertically integrated ambulatory care and community-centric services, ensures that members receive the right care at the right time in the most efficient setting. The goal of CareMax is to intercede as early as possible to manage chronic conditions for its patients in a proactive, holistic, and tailored manner. This intervention has a significant positive influence on patient outcomes and overall healthcare costs.

This comprehensive, high touch approach to health care delivery, powered by the Care Optimize technology platform, has proven to reduce hospital admissions, ER visits, and readmission rates when compared to Medicare’s Fee for Service (FFS) benchmarks, and improve patient outcomes and satisfaction.

The Company specifically focuses on providing access to high quality care in underserved communities, with approximately 64% of its Medicare Advantage patients being dual-eligible and low-income subsidy eligible.

The Company’s strong regional presence in South Florida is complemented by its national reach through CareOptimize software and services offerings. The operating and technology platform, used by 20,000 providers, improves patient outcomes, drives accountability, and lowers healthcare spending through the delivery and support of customized care with a focus on preventative chronic disease management and the social determinants of health.

“CareMax plays a significant role in the lives of our members by providing accessible, quality medical care and comprehensive social activities and services,” said Mr. de Solo. “Seniors represent the most significant opportunity to lower the national healthcare spend, and we believe that CareMax possesses the technology, knowledge and know-how to continue to bend this cost curve. We are very excited about the prospects of combining with DFHT and look forward to this next, exciting phase of our growth.”

“Value-based care, built upon the premise of providing extensive primary care, is recognized as an effective way to lower healthcare costs and improve patient outcomes in Medicare Advantage, especially for dual eligible beneficiaries and those with chronic conditions. We believe that CareMax operates a best-in-class delivery model supported by a highly scalable technology backbone,” said Mr. Barasch. “We believe this business combination will create a well-capitalized platform, well-positioned to expand organically, through accretive M&A activity and through strategic partnerships with payors.”

“We are excited to invest and partner with DFHT as part of the combination of these two best-in-class, value-based primary care organizations. Primary care has always been the gatekeeper for most healthcare spend, and we believe this model represents the best way to improve quality outcomes and manage costs across the healthcare continuum,” said Roger Marrero, Senior Partner of Comvest Partners.

Growth

CareMax will pursue a strategy of organic growth and selected acquisitions in a highly fragmented industry. The Company forecasts organic revenue growth of 15% from Pro Forma CY2020(E) through CY2023(E), which could increase substantially if the Company executes on acquisitions.

CareMax will also pursue strategic partnerships to build de novo clinics to serve Medicare Advantage members in and out of Florida. We are pleased to announce that CareMax and Anthem will be expanding their current relationship with plans to open new senior care centers in the eastern region of the United States. Details will be announced at a later date as these plans are formalized.

The business combination, which has been approved by the board of directors of DFHT and the governing bodies of CareMax Medical Centers and IMC Health, is expected to close in the first quarter of 2021, subject to customary conditions, including the approval by DFHT stockholders.

A more detailed description of the transaction terms and a copy of the business combination agreement will be included in a current report on Form 8-K to be filed by DFHT with the United States Securities & Exchange Commission (“SEC”). DFHT will file a proxy statement with the SEC in connection with the transaction.

Deutsche Bank Securities Inc. and UBS Investment Bank are acting as financial advisors and capital markets advisors to DFHT. Morgan Stanley & Co. LLC is acting as financial advisor to CareMax Medical Centers and Piper Sandler is acting as financial advisor to IMC Health. White & Case LLP and Polsinelli PC are acting as legal advisors to DFHT, DLA Piper LLP (US) is acting as legal advisor to CareMax Medical Centers, McDermott Will & Emery LLP is acting as legal advisor to IMC Health and Katten Muchin Rosenman LLP is acting as legal advisor to Deerfield.

Management Presentation Information

The management of CareMax and DFHT will make a presentation via webcast regarding the business combination on December 18, 2020 at 12 pm EST. In connection with this event, DFHT will furnish an investor presentation in a current report on Form 8-K to be filed by DFHT with the United States Securities & Exchange Commission (“SEC”).

Please dial 877-407-9753 or 201-493-6739 or https://78449.themediaframe.com/dataconf/productusers/drf/mediaframe/42589/indexl.html

A replay of the event may be accessed by dialing 877-660-6853 or 201-612-7415 and using Conference ID #13714399.

About CareMax Inc.

CareMax, comprised of the existing CareMax Medical Centers, IMC Health, and CareOptimize, is a technology-enabled care platform providing value-based care and chronic disease management to Seniors. Collectively, the Company operates 26 wholly owned medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

About Deerfield Healthcare Technology Acquisitions Corp.

Deerfield Healthcare Technology Acquisitions Corp. is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company’s sponsor is an affiliate of Deerfield Management Company, L.P., an investment firm focused exclusively on the healthcare industry, and Richard Barasch, a veteran healthcare public company executive and investor.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com

Important Information and Where to Find It

In connection with the proposed business combination, DFHT intends to file with the SEC a preliminary proxy statement relating to the business combination. DFHT will mail a definitive proxy statement and other relevant documents to the stockholders of DFHT. Stockholders of DFHT and other interested persons are advised to read, when available, the preliminary proxy statement, and amendments thereto, and, when available, the definitive proxy statement and any amendments thereto in connection with DFHT’s solicitation of proxies for the special meeting to be held to approve the business combination because these proxy statements will contain important information about DFHT, CareMax Medical Centers, IMC Health and the business combination. The definitive proxy statement will be mailed to stockholders of DFHT as of a record date to be established for voting on the business combination. Stockholders will also be able to obtain copies of the proxy statement, without charge, once available, at the SEC’s Internet site at http://www.sec.gov or by directing a request to: Deerfield Healthcare Technology Acquisitions Corp., 780 Third Avenue, New York, NY 10017, Attention: Secretary, or by calling (212) 551-1600.

Participants in the Solicitation

DFHT, CareMax Medical Centers and IMC Health, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the proposed business combination under the rules of the SEC. Information about the directors and executive officers of DFHT is set forth in DFHT’s registration statement on Form S-1, which was initially filed with the SEC on June 30, 2020 and is available free of charge from the sources indicated above.

Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders in connection with the proposed business combination will be set forth in the preliminary and definitive proxy statement when filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Non-Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, the expectation that the Company’s common stock will be listed on Nasdaq, and the anticipated closing date of the proposed business combination. These statements are based on various assumptions and on the current expectations of DFHT, CareMax Medical Centers and IMC Health management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DFHT, CareMax Medical Centers and IMC Health. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which CareMax Medical Centers or IMC Health may become a party or governmental investigations to which CareMax Medical Centers or IMC Health may become subject that could interrupt or limit CareMax Medical Centers’ or IMC Health’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in CareMax Medical Centers’ or IMC Health’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the inability of the parties to successfully or timely consummate the proposed business combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination or that the approval of the stockholders of DFHT and/or the equity holders of CareMax Medical Centers or IMC Health for the proposed business combination is not obtained; failure to realize the anticipated benefits of the proposed business combination, including as a result of a delay in consummating the proposed business combination or a delay or difficulty in integrating the businesses of DFHT, CareMax Medical Centers and IMC Health; the amount of redemption requests made by DFHT’s stockholders; those factors discussed in DFHT’s registration statement on Form S-1, which was initially filed with the SEC on June 30, 2020, under the heading “Risk Factors,” and other documents of DFHT filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DFHT, CareMax Medical Centers nor IMC Health presently know or that DFHT, CareMax and IMC Health currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DFHT’s, CareMax Medical Centers’ and IMC Health’s expectations, plans or forecasts of future events and views as of the date of this press release. DFHT, CareMax Medical Centers and IMC Health anticipate that subsequent events and developments will cause DFHT’s, CareMax’s Medical Centers’ and IMC Health’s assessments to change. DFHT, CareMax Medical Centers and IMC Health or CareOptimize do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing DFHT’s, CareMax Medical Centers’ and IMC Health’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Non-GAAP Financial Measures

The financial information and data contained in this press release is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in, any proxy statement or registration statement to be filed by DFHT, CareMax Medical Centers, IMC Health or CareOptimize with the SEC. Some of the financial information and data contained in this press release, such as adjusted EBITDA, has not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). A reconciliation of certain of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table in the investor presentation.

DFHT, CareMax Medical Centers, IMC Health and CareOptimize believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to CareMax’s financial condition and results of operations. DFHT, CareMax Medical Centers, IMC Health and CareOptimize believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing CareMax’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of CareMax does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in CareMax Medical Centers’ financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review CareMax Medical Centers’ audited financial statements, which will be presented in DFHT’s proxy statement to be filed with the SEC, and not rely on any single financial measure to evaluate CareMax Medical Centers’ business.

DFHT Healthcare

Chris Wolfe

[email protected]

(917)923-7629

DFHT Investor Relations

The Equity Group Inc.

Devin Sullivan

Senior Vice President

[email protected]

(212) 836-9608

KEYWORDS: Florida New York United States North America

INDUSTRY KEYWORDS: Managed Care General Health Health

MEDIA:

Logo
Logo

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. (CVIAQ) Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. (CVIAQ) Investors

Shareholders with losses exceeding $400,000 are encouraged to contact the firm

BENSALEM, Pa.–(BUSINESS WIRE)–
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Covia Holdings Corporation (“Covia” or the “Company”) f/k/a Fairmount Santrol Holdings Inc. (“Fairmount Santrol”) (OTC: CVIAQ) (NYSE: CVIA, FMSA) securities between March 15, 2016 and June 29, 2020, inclusive (the “Class Period”). Covia investors have until February 8, 2021 to file a lead plaintiff motion.

Investors suffering losses on their Covia investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

Covia provides minerals and materials solutions for the industrial and energy markets, including producing proprietary sand for use in fracking.

On March 22, 2019, after the market closed, the Company disclosed that it had “received a subpoena from the SEC seeking information relating to certain value-added proppants marketed and sold by Fairmount Santrol or Covia within the Energy segment since January 1, 2014.”

On this news, the Company’s share price fell $0.45, or 7%, to close at $6.05 per share on March 25, 2019, thereby injuring investors.

Then, on November 6, 2019, during market hours, Covia disclosed that “the SEC ha[d] requested additional information and subpoenaed certain current and former employees to testify.”

On this news, the Company’s share price fell $0.07, or 4.3%, to close at $1.56 per share on November 6, 2019, thereby injuring investors further.

Then, on June 29, 2020, after the market closed, the Company announced that it had filed for petitions under Chapter 11 of the U.S. Bankruptcy Code.

On June 30, 2020, the NYSE delisted the Company, stating in relevant part that “the Company is no longer suitable for listing . . . after the Company’s June 29, 2020 disclosure that the Company filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code.”

On this news, the Company’s share price fell $0.18, or more than 37%, between the closing price on NYSE and resuming trading OTC on July 1, 2020 at $0.30 per share.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Covia’s proprietary “value-added” proppants were not necessarily more effective than ordinary sand; (2) Covia’s revenues, which were dependent on its proprietary “value-added” proppants, was based on misrepresentations; (3) when Covia insiders raised this issue, defendants did not take meaningful steps to rectify the issue; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Covia securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

[email protected]

www.howardsmithlaw.com

 

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA: